Vaccinex, based in Rochester, NY, is a pioneering brand (Nasdaq: VCNX) at the forefront of cancer and neurologic disease treatment. They have revolutionized the field with their unique approach, inhibiting semaphorin 4D (SEMA4D). This powerful biological effector is believed to prevent immune infiltration, induce myeloid suppressor cells in tumors, and promote neuroinflammation in the brain through reactive gliosis.

Vaccinex's lead drug candidate, pepinemab, effectively blocks SEMA4D, enhancing immune activity against tumors and targeting underlying pathogenic immune mechanisms. This has the potential to combat chronic neurological disorders like Alzheimer's and Huntington's disease. With their proprietary drug discovery platform, ActivMAb®, Vaccinex aims to expand their pipeline and establish strategic collaborations.

They are committed to research and development, conducting clinical trials in both neurology and oncology. Stay updated with Vaccinex's contribution to medical science through their news and publications. Investors can find comprehensive financial information, news releases, and presentations on their website.

If you're passionate about making a difference in healthcare, consider joining Vaccinex's team. Get in touch with them to learn more about their exciting work